Overview: Liver Fibrosis Panel
Introduction: The Liver Fibrosis Panel is a diagnostic tool designed to assess liver fibrosis using serum samples. In India, liver fibrosis/cirrhosis affects ~10-15 percent of adults (NAFLD ~20-30 percent urban, alcohol/viral hepatitis in rural), progressing silently to decompensated disease or HCC. High morbidity from under-testing in rural/low-SES patients with metabolic risk or chronic hepatitis, limited non-invasive labs, delayed fibrosis staging leading to missed early intervention or transplant. Per hepatology practices aligned with ICMR and INASL guidelines, the test employs spectrophotometry for 23 fibrosis markers (ALT, AST, GGT, platelets-derived indices: Fib-4, APRI, NAFLD fibrosis score, etc.) over 1-2 days with high accuracy, valuable for non-invasive fibrosis staging as alternative to biopsy. This diagnostic falls under liver function screening and targets patients with NAFLD, chronic hepatitis, or alcohol use, addressing accurate detection to guide lifestyle modification, antivirals, or surveillance. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise fibrosis assessment and reducing cirrhosis/HCC burden. Its serum-based approach ensures reliable biomarker calculation.
Other Names: Liver Fibrosis Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.
Historical Milestone: Non-invasive fibrosis scores standard; in India, expanding in NAFLD clinics.
Purpose: The test assesses 23 parameters including fibrosis markers to guide liver fibrosis assessment, stage severity, inform management.
Test Parameters: 1â€"23. Fibrosis Markers (ALT, AST, GGT, Fib-4, APRI, etc.).
Pretest Condition: Fasting 10-12 hours recommended; patients should have liver risk factors.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on alcohol, diabetes, viral hepatitis.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected fibrosis including cirrhosis, benefits of non-invasive screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and calculate scores within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or thrombocytopenia can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: High Fib-4/APRI indicates advanced fibrosis, necessitating specialist input.
Specialist Consultation: Hepatologists should be consulted for management.
Additional Supporting Tests: FibroScan, elastography for confirmation.
Test Limitations: Indirect markers; comprehensive approach required.
References: Indian Journal of Gastroenterology 2024, Liver Studies India 2023.
